ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
| あなたへ/カタログ番号 | 在庫状況 | 単価 |
|---|
この商品について
実験式（ヒル表記法）:
C15H15ClN2OS
CAS番号:
分子量:
306.81
MDL number:
NACRES:
NA.24
UNSPSC Code:
41116107
現在、価格および在庫状況を閲覧できません。
grade
pharmaceutical analytical impurity (PAI)
agency
USP
API family
clopidogrel
manufacturer/tradename
USP
application(s)
pharmaceutical small molecule
format
neat
storage temp.
2-8°C
General description
Find answers to frequently asked questions on USP products in USP FAQs.
Clopidogrel R-Enantiomer is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Clopidogrel Bisulfate
Therapeutic Area: Cardiovascular
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Clopidogrel Bisulfate
Therapeutic Area: Cardiovascular
Application
Clopidogrel R-Enantiomer is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.
Features and Benefits
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable